Transforming the Company into a Highly Profitable Enterprise through Selectivity and Focus
First written in FY2018. 10 of 22 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2026.
84 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Based on this understanding, the Group formulated a new long-term management target for the fiscal year ending March 2033 in order to dramatically accelerate its growth toward achieving the “No. 1 in Asia” vision described above.」
The previous focus on selective concentration and transformation into a highly profitable company has been translated into a long-term management target for the fiscal year ending March 2033. The Group has identified strengthening competitiveness, accelerating globalization and pursuing new businesses as its basic strategies, and aims to achieve revenue of ¥80 billion and operating profit of ¥10 billion in the fiscal year ending March 2033. - FY2026-H1ReframedAnnual report
「The Group formulated a long-term management vision to achieve unprecedented, significant growth through business expansion. With “Lead in Asia. Challenge the World.” as its vision, or the state it aspires to achieve, the Group aims to become the No. 1 company in Asia by revenue in the gelatin and collagen industry, while working to further accelerate its growth and enhance corporate value.」
The framework has been reorganized from a medium-term plan centered on selective concentration and transformation into a highly profitable company to one focused on business expansion, significant growth and becoming No. 1 in Asia by revenue under the long-term management vision. - FY2025AdvancedAnnual report
「Against this backdrop, the Group launched its “2024-2026 Medium-Term Management Plan” (the “Plan”) in April 2024 to transform itself into a highly profitable company and achieve sustainable growth. The three-year period through the fiscal year ending March 2027 is positioned as a period for fundamentally strengthening earnings power and cash generation, and initiatives are under way.」
The Group has organized its shift toward selective concentration and a highly profitable business structure as a three-year medium-term management plan beginning in April 2024, positioning the period through the fiscal year ending March 2027 as one for fundamentally strengthening earnings power and cash generation. For the fiscal year ended March 2025, operating profit was ¥3,930 million and ROE was 16.3%. - FY2025-H1ReframedAnnual report
「The Group has adopted “Contributing to improving people's QOL through collagen” as its long-term vision. To become a highly profitable company and achieve sustainable growth, it launched a new medium-term management plan covering the three years from the current fiscal year, from the fiscal year ending March 2025 through the fiscal year ending March 2027, as a period for fundamentally strengthening earnings power and cash-generation capacity.」
The previous policy of selectivity and concentration and transformation into a highly profitable business has been recast as a medium-term management plan to fundamentally strengthen earnings power and cash-generation capacity over the three years from the fiscal year ending March 2025 through the fiscal year ending March 2027. - FY2024-Q3AdvancedAnnual report
「After extensive discussions and careful consideration of initiatives concerning its North American market operations and business turnaround, the Group decided to cease production at Nitta Gelatin USA Inc. on the basis of its judgment that streamlining the North American business and concentrating resources on future growth areas would enhance the corporate value of the Group as a whole.」
Regarding the transformation into a highly profitable business through selectivity and concentration, the Group moved to the implementation stage by streamlining its North American business, concentrating resources on growth areas and deciding to cease production at its U.S. subsidiary. - FY2024-Q2RestatedAnnual report
「The group has set its long-term vision as “contributing to improving people’s QOL through collagen,” and its business strategy is to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」
The Group continues a policy corresponding to its previous focus on selectivity and concentration and transformation into a highly profitable business as a business strategy that includes a shift to collagen peptides and allocation of resources to growth markets. - FY2024-Q1RestatedAnnual report
「The business strategy is to shift from commodity gelatin to higher-value-added collagen peptides, allocate management resources strategically to markets with growth potential, and transform the company into a highly profitable business.」
The Group continues a policy corresponding to its previous focus on selectivity and concentration and transformation into a highly profitable business as a business strategy that includes a shift to collagen peptides and allocation of resources to growth markets. - FY2023-Q3RestatedAnnual report
「In June 2022, the group announced a business strategy under which its 10-year vision would be to “contribute to improving people’s QOL through collagen,” with specific measures to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」
The Group continues a policy corresponding to its previous focus on selectivity and concentration and transformation into a highly profitable business as a 10-year business strategy that includes a shift to collagen peptides and priority allocation of resources to growth markets. - FY2023-Q2RestatedAnnual report
「In June 2022, the group announced a business strategy under which its 10-year vision would be to “contribute to improving people’s QOL through collagen,” with specific measures to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」
The Group continues its previous policy of selectivity and concentration and transforming into a highly profitable business, framed as its 10-year vision and a shift in its business mix toward collagen peptides. - FY2023-Q1ReframedAnnual report
「On 8 June 2022, the group announced a business strategy setting out its vision for 10 years from then. It declared that its 10-year vision was to “contribute to improving people’s QOL through collagen” and, as specific measures, to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」
The previous focus on “selectivity and concentration” and a “highly profitable business” was recast as a business strategy for the 10-year vision that combines a shift from general-purpose gelatin to collagen peptides with priority allocation of resources to growth markets. - FY2022-Q1ReframedAnnual report
「1. Allocate management resources primarily to focus markets and become a highly profitable company」
The previous policy of “pursuing selectivity and concentration, creating high-value-added products and services, and transforming the Group into a more profitable business” was recast as a new medium-term management plan policy of identifying focus markets, allocating management resources primarily to them and increasing profitability. - FY2021AdvancedAnnual report
「As part of its policy of focusing on selected businesses, the company completed the transfer of its adhesives manufacturing business to ボスティック・ニッタ株式会社, an equity-method affiliate, in February 2021.」
To focus on the Collagen Business and transform into a highly profitable business, the Group made concrete progress in reorganizing its portfolio by completing the transfer of the manufacturing division of the adhesives business. - FY2021-Q2AdvancedAnnual report
「Following the decision to withdraw from the adhesives business, the carrying amount was reduced to the recoverable amount because profitability was no longer expected, and the reduction was recorded as an impairment loss.」
Regarding the review of the business portfolio through selectivity and concentration, the decision to withdraw from the adhesives business took concrete shape, and an impairment loss of ¥44 million was recognized on related assets. - FY2020-Q3AdvancedAnnual report
「As part of its policy of focusing on selected businesses, the Company transferred all shares of Nitta Casings Inc., formerly a specified subsidiary, and Nitta Casings (Canada) Inc., formerly a consolidated subsidiary, in December 2019.」
To transform into a highly profitable business through selectivity and concentration, the Group completed the transfer of all shares in its 2 North American casing subsidiaries in December 2019. - FY2020-Q1AdvancedAnnual report
「新田ゼラチンフーズ株式会社, formerly a consolidated subsidiary of the Company, was dissolved through its absorption merger with the Company effective 1 April 2019 and was therefore excluded from the scope of consolidation from the first quarter of the current consolidated fiscal year.」
The planned absorption merger of the sales subsidiary, undertaken to focus on core areas and expand the business, was completed effective 1 April 2019, and the subsidiary was excluded from the scope of consolidation. - FY2019-Q3AdvancedAnnual report
「With the aim of focusing on its core areas and expanding its business, the Group decided to absorb and merge its sales subsidiary, 新田ゼラチンフーズ株式会社, effective 1 April 2019.」
To focus on its core areas and expand its business, it made the specific decision to absorb and merge its sales subsidiary effective 1 April 2019. - FY2019-Q2AdvancedAnnual report
「The Group's reportable segments had previously been divided into two businesses, the Collagen Materials Business and the Formula Solutions Business. Under its policy of promoting strategies in core businesses and making concentrated investments in new businesses, the Group reorganized its organization, mainly by changing its production and sales management structure, and reviewed the allocation of management resources and its management structure. In addition, on 1 August 2018, the Group carried out a company split of the adhesives business, excluding manufacturing, which was included in the Formula Solutions Business. As the Group shifted to an integrated management structure for its business activities as the Collagen Business, it changed to a single reportable segment, the Collagen Business, from the second quarter of the current consolidated fiscal year.」
The Group carried out an organizational reorganization of its production and sales management structure and a company split of the adhesives business, moving to the specific stage of managing the Collagen Business as a single integrated segment. - FY2019-Q1RestatedAnnual report
「The Group launched a new three-year medium-term management plan in April 2018. …3. Pursue selectivity and concentration, create high-value-added products and services, and transform the Group into a more profitable business.」
The new three-year plan also continues the management policies of selectivity and concentration, creating high-value-added products and services, and transforming the Group into a highly profitable business. - FY2018First statedAnnual report
「3. Pursue selectivity and concentration, create high-value-added products and services, and transform the Group into a more profitable business.」
It newly identified the goal of transforming the Group into a highly profitable business through strategic advancement in core businesses, concentrated investment in new businesses and optimization of the product portfolio.